This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zuckerman, S. H. Articles by Bryan-Poole, N. Search for Related Content PubMed PubMed Citation Articles by Zuckerman, S. H. Articles by Bryan-Poole, N. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Lupus

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:1556-1562.)
© 1995 American Heart Association, Inc.

Articles

Estrogen-Induced Alterations in Lipoprotein Metabolism in Autoimmune MRL/lpr Mice

Steven H. Zuckerman; Nancy Bryan-Poole

From the Division of Cardiovascular Research, Lilly Research Labs, Indianapolis, Ind.

Correspondence to Steven H. Zuckerman, Division of Cardiovascular Research, Lilly Research Labs, Indianapolis, IN 46285.

Abstract Estrogen replacement therapy has been demonstrated to shift the lipoprotein profile toward a less atherogenic one with concomitant increases in HDL and reductions in LDL cholesterol and serum triglycerides. Estrogen, however, has also been implicated in playing a significant role in autoimmune disease and may be involved with disease incidence and progression. The MRL/lpr mouse strain represents an autoimmune disease model with features resembling systemic lupus erythematosus including high-titer autoantibodies, glomerulonephritis, and vasculitis. In the present study, the effects of estrogen treatment on serum lipoprotein profiles were investigated by fast protein liquid chromatography in female MRL/lpr mice, in the MRL/++ strain with a milder form of disease, and in control Balb/c mice. Treatment of MRL/lpr mice for periods of 1 week or longer with pharmacologic doses of estrogen resulted in a significant increase in the amount of cholesterol carried on LDL particles. The up to eightfold increase in LDL cholesterol was less significant in the MRL/++ or Balb/c mice. Maximal increases were observed at 1 to 2 mg/kg of estrogen agonists, and the effect on LDL cholesterol increases was inhibited by tamoxifen. The HDL-to-LDL shift in cholesterol observed in estrogen-treated autoimmune mice correlated with an increase in apolipoprotein E, primarily on larger HDL particles. In addition to the increase in LDL cholesterol, hormonal treatment also resulted in a shift in triglycerides from the VLDL to the LDL fraction in both normal and autoimmune mice. These results suggest that pharmacologic doses of estrogen may contribute to cardiovascular disease progression by shifting the relative distribution of cholesterol from HDL to LDL in this murine model of lupus.

Key Words: estrogen • autoimmune • low-density lipoproteins • cholesterol

This article has been cited by other articles:

				S. H. Zuckerman, G. F. Evans, J. A. Schelm, P. I. Eacho, and G. Sandusky Estrogen-Mediated Increases in LDL Cholesterol and Foam Cell–Containing Lesions in Human ApoB100CETP Transgenic Mice Arterioscler Thromb Vasc Biol, June 1, 1999; 19(6): 1476 - 1483. [Abstract] [Full Text] [PDF]